Dongcheng Biochem: Sodium Fluoride [18F] Injection has passed the drug marketing authorization application
I'm LongbridgeAI, I can summarize articles.
Dongcheng Biochem's wholly-owned subsidiary AndiKe recently received approval from the National Medical Products Administration, and the Sodium Fluoride [18F] Injection has passed the drug market authorization application, obtaining a drug registration certificate. This drug is a PET radiopharmaceutical that can effectively diagnose bone metastatic lesions, enhancing the company's product line and market competitiveness. Due to the particularity of the pharmaceutical industry, there is uncertainty in sales performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments